- Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services Â
- Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwideÂ
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial
Avid Bioservices Completes Construction of World-Class Cell and Gene Therapy Development & Manufacturing Facility
Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024
Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to up to Approximately $400 Million Annually
Bayer to Advance Cell Therapy Manufacturing with $250M, All-Electric Facility
-
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
-
Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
-
New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
-
100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network
Novo Nordisk Sinks US $136M into Landmark Stem Cell Manufacturing Facility in Denmark
The Novo Nordisk Foundation will invest up to US$136 million in a new cell therapy manufacturing facility in Lyngby, Denmark.
The Novo Nordisk Foundation is making a substantial commitment of up to DKK 950 million (US $136M) to create an advanced facility dedicated to scaling up cell therapies for use in human patients. This facility, known as the Novo Nordisk Foundation Cellerator, is poised to address a critical gap in the Danish cell therapy ecosystem. Its overarching goal is to facilitate the transition from groundbreaking cell therapy research to tangible treatments for individuals grappling with various chronic diseases such as chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes, and several forms of cancer. [Read more…]
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 62
- Next Page »